Hesperos and Bayer Consumer Health develop frst human-on-a-chip model of stress-induced cognitive dysfunction

New study presents a human-relevant stress model for assessing potential therapeutics

Bayer inaugurates new phytomedicines lab facility

The lab will facilitate the development of herbal and natural-based solutions

Bayer launches biotech innovation platform in China

Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks

Bayer presents Phase III VICTOR clinical trial data of vericiguat at ESC Congress 2025

The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged

Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer

European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Corona Remedies acquires 7 brands from Bayer's pharma division in India

This marks the fourth acquisition by Corona Remedies from multinational corporations

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,

DKSH and Bayer partner across multiple markets in Southeast Asia

Bayer submits EU application for Gadoquatrane MRI contrast agent

It is intended for contrast enhancement in MRI scans

Bayer receives first approval for Lynkuet in UK as treatment for vasomotor symptoms associated with menopause

The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials